Core Insights - Tempus AI reported Q3 2025 revenue of $334.2 million, a significant increase of 84.7% year-over-year, surpassing market expectations of $328.73 million [1] - The company experienced a net loss of $80 million in Q3, which is wider than the $75.8 million loss in the same period last year, influenced by one-time expenses [1] - The adjusted EBITDA for Q3 was $1.5 million, a recovery from a loss of $21.8 million in the previous year [2] Revenue Breakdown - Genomics revenue reached $252.9 million, up 117.2% year-over-year, with tumor testing contributing $139.5 million, a 31.7% increase [2] - Genetic testing revenue from Ambry Genetics was $102.6 million, reflecting a 32.8% increase, while data and services revenue grew by 26.1% to $81.3 million [2] - The gross profit for Q3 was $209.9 million, marking a 98.4% increase compared to the previous year [2] Operational Highlights - The company acquired digital pathology AI firm Paige to enhance its data set and technical team [3] - Tempus AI was selected by ARPA-H for the ADAPT program to provide testing and CRO services [3] - The company received FDA 510(k) clearance for several products, including xR IVD and Tempus Pixel cardiac imaging platform [3] Future Outlook - Tempus AI raised its full-year 2025 revenue guidance to approximately $1.265 billion, representing an expected growth of about 80% [3] - The company anticipates an adjusted EBITDA of approximately $20 million for Q4, with a slight positive adjusted EBITDA for the full year [3] Financial Position - As of the end of the quarter, Tempus AI held $764.3 million in cash and securities [4]